Efficacy and Safety Study of TissueGene-C to Degenerative Arthritis

Degenerative Arthritis Clinical Trial

Official title:

A Multicenter, Single-blind, Phase 2A Clinical Trial to Evaluate the Efficacy and Safety of TissueGene-C, a Cell-mediated Gene Therapy, in Degenerative Arthritis Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02341378
• Other study ID #: TCG-K1-02
• Status: Completed
• Phase: Phase 2
• First received: January 8, 2015
• Last updated: January 21, 2015
• Start date: August 2009
• Est. completion date: October 2010

Study information

• Verified date: January 2015
• Source: Kolon Life Science
• Contact: n/a
• Is FDA regulated: No
• Health authority: Korea: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

To assess the efficacy and safety of the intra-articular injection of TissueGene-C in patients with degenerative arthritis of the knee

Description:

TissueGene-C is a biological new drug which consists of non-transduced chondrocytes and transduced chondrocytes that express Transforming Growth Factor(TGF)-b1 to regenerate the damaged cartilage.

During the clinical trial Phase 2A, we compare low dose or high dose TissueGene-C in 6 months trial with 28 outpatients who have degenerative arthritis. The patients are randomized to two dose levels of TisssueGene-C by 1:1 ratio, and they are monitored and recorded for alleviating symptoms, sports activities, function of the knee, and the presence of adverse events.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 28
• Est. completion date: October 2010
• Est. primary completion date: June 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 45 Years and older

Eligibility

Inclusion Criteria:

1. Male or female, aged 45 years or more

2. With grade 4 degenerative arthritis of the knee [based on the International Cartilage Repair Society(ICRS) evaluation criteria from the MRI results]

3. With less than 6 cm2major lesions

4. With major lesions (grade 4) concentrated in only one section of the knee and considered the main cause of the clinical symptoms

5. Unresponsive to conventional symptomatic treatment

6. Healthy and with no major physical examination, hematology, serum chemistry, and urine test findings and no significant medical history

7. Agreed to use an effective contraceptive method during the study period

8. Voluntarily agreed to participate in this study and signed the Informed Consent Form

Exclusion Criteria:

1. Abnormal screening laboratory test (hematology, serum, and urine test) findings

2. Took anti-inflammatory medications (prescribed or over-the-counter), including natural medicines, within 14 days before the injection of the investigational product

3. Took antirheumatic drugs (e.g., methotrexate or antimetabolites) within three months before enrollment in this study

4. Has a history of drug abuse within one year from the enrolment, or has positive results in the urine drug test or serum alcohol test at the screening visit

5. Received an injection in the target knee within two months before enrollment in this study

6. Pregnant or breastfeeding female

7. With another joint disease apart from degenerative arthritis (e.g., systemic rheumatic inflammatory disease associated with the knee or chondrocalcinosis, hemachromatosis, inflammatory arthritis, necrosis of the trochanter, Paget's disease adjacent to a joint in the femur or tibia, ochronosis, hemophilic arthropathy, infectious arthritis, Charcot's disease in the knee joint, villonodular synovitis, and synovial chondromas)

8. With a current infectious disease, including HIV or hepatitis

9. Has any of the following clinically significant diseases:

• heart disease [e.g., myocardial infarction, arrhythmia, other serious heart disease, coronary artery bypass graft (CABG)]

• kidney disease (e.g., chronic renal failure, glomerulonephritis)

• liver disease (e.g., liver cirrhosis, fatty liver, acute or chronic liver disease)

• endocrine disease (e.g., hyperthyroidism, hypothyroidism, thyroiditis, diabetes insipidus, Cushing's disease)

• insulin-dependent diabetes mellitus

• medical history of or current malignant tumor

• In particular, the tumors that TissueGene-C may aggravate can be screened using the following tests:

• Leukemia: White Blood Cell level in the hematology

• Osteochondroma, Chondromas, Chondroblastoma, Chondromyxoid fibroma, Chondrosarcoma : Alkaline phosphatase level in the hematology

10. Participated in another clinical trial (using the investigational drug or a medical device) within 30 days before enrollment in this study

11. Considered by the investigator inappropriate for participation in this study

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Arthritis
• Degenerative Arthritis
• Osteoarthritis

Intervention

Biological:
• TissueGene-C(Low dose)
TissueGene-C at 6.0x10^6 cells
• TissueGene-C(High dose)
TissueGene-C at 1.8x10^7 cells

Locations

Country	Name	City	State
Korea, Republic of	Samsung Medical Center	Gangnam-gu	Seoul
Korea, Republic of	Asan Medical Center	Seoul
Korea, Republic of	Seoul National Univ. Hospital	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
Kolon Life Science

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in IKDC Subjective Knee Evaluation	Symptoms, sports activities, and function of the knee will be measured by the International Knee Documentation Committee (IKDC)	Week 0, 12 and 24	No
Secondary	Changes in WOMAC scores	Pain, stiffness, and physical function of the knee will be measured by the Western Ontario and McMaster Universities(WOMAC)	Week 0, 12 and 24	No
Secondary	Changes in 100 mm-VAS	Pain of the knee will be measured by the 100mm Visual Analogue Scale (VAS)	Week 0, 12 and 24	No
Secondary	Comparative Evaluation of Knee MRI	Change in the Magnetic Resonance Images (MRI) scan results after the administration of TissueGene-C	Week 0, 12 and 24	No
Secondary	Number of Participants with Adverse Events	Allergic reaction, Injection site reaction , Infection in the injection site, Fibrosis, Fibrosis-deep connective tissue, Muscular/skeletal hypoplasia, TGF-ß1 Enzyme-linked Immunosorbent Assay (ELISA) result, Polymerase Chain Reaction(PCR) for the vector DNA test results	Week 0, 2, 4, 12 and 24	Yes
Secondary	Evaluation of Physical examination and laboratory tests	Vital signs, Physical examination findings, Monitoring of the hematology, serum chemistry, and urine test results	Week 0, 2, 4, 12 and 24	Yes